Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
ZC6s58BejjR2yB1t
Listen
